CellCentric

CellCentric is a UK-based anticancer drug developer. Its candidate drug, CCS1477, is an orally available inhibitor of histone acetyltransferases p300 and CBP that targets the conserved bromodomain of these two proteins and is applicable for the treatment of prostate cancer.